Metastatic Basal Cell Carcinoma Accompanying Gorlin Syndrome

Abstract

Gorlin-Goltz syndrome or basal cell nevus syndrome is an autosomal dominant syndrome characterized by skeletal anomalies, numerous cysts observed in the jaw, and multiple basal cell carcinoma of the skin, which may be accompanied by falx cerebri calcification. Basal cell carcinoma is the most commonly skin tumor with slow clinical course and low metastatic potential. Its concomitance with Gorlin syndrome, resulting from a mutation in a tumor suppressor gene, may substantially change morbidity and mortality. A 66-year-old male patient with a history of recurrent basal cell carcinoma was presented with exophthalmus in the left eye and the lesions localized in the left lateral orbita and left zygomatic area. His physical examination revealed hearing loss, gapped teeth, highly arched palate, and frontal prominence. Left orbital mass, cystic masses at frontal and ethmoidal sinuses, and multiple pulmonary nodules were detected at CT scans. Basal cell carcinoma was diagnosed from biopsy of ethmoid sinus. Based on the clinical and typical radiological characteristics (falx cerebri calcification, bifid costa, and odontogenic cysts), the patient was diagnosed with metastatic skin basal cell carcinoma accompanied by Gorlin syndrome. Our case is a basal cell carcinoma with aggressive course accompanying a rarely seen syndrome.

Gorlin–Goltz syndrome: A case series of 5 patients in North Indian population with comparative analysis of literature

“…Although BCC has a low metastatic potential of 0.0028–0.55%, recently an NBCCS patient had been diagnosed with recurrent BCC with lung metastasis. [ 56 ] As cumulative ultraviolet (UV) light is the main risk factor, these patients are warned against prolonged sun exposure.…”

A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo

“…As a result, the active SMO triggers a downstream signalling cascade, which leads to the activation of GLI transcription factors (Gli1, Gli2 and Gli3) that translocate into the nucleus and induce the expression of their target genes including GLI1 and PTCH1, among others which are pro-tumorigenic [7,8]. Nevertheless, in several cancers including basal cell carcinoma (BCC) and medulloblastoma (MB), HH pathway is constitutively activated and related to ligand-independent mechanism, due to somatic mutations in PTCH1, SMO or SUFU genes [9]. Conversely, ligand-dependent activation has been shown in other malignancies, such as melanoma, pancreatic, lung, breast, renal, and colorectal cancers [2,6].…”

Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo

“…Ligand-independent mechanisms can also be responsible for the constitutive Hh pathway activity in cancers. Ligand-independent constitutive activation of the Hh pathway, found in basal cell carcinoma (BCC) and medulloblastoma, is characterized by the presence of somatic mutations in Ptch1, Smo or SUFU genes [5]. On the other hand, the liganddependent activation observed in a wide range of cancers including melanoma, pancreatic, lung, breast, renal, and colorectal cancers [1,3], is associated with elevated production of Hh ligands by tumor or stromal cells [2].…”